NMPA approves Gyre’s avatrombopag maleate tablets for TP associated with CLD

Gyre Therapeutics announced that China’s National Medical Products Administration or NMPA has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets for the treatment of thrombocytopenia or TP associated with chronic liver disease, CLD,,in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life-threatening in severe cases. “The approval of avatrombopag maleate tablets by the NMPA represents an important milestone for Gyre as we expand our rare disease product lines and build our presence in developing treatments for patients with CLD,” said Han Ying, Ph.D., CEO of Gyre Therapeutics. “We are eager to launch avatrombopag in China and provide a treatment for patients suffering from this devastating disease.”